Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT
- First Online:
- Cite this article as:
- Krüger, S., Buck, A.K., Mottaghy, F.M. et al. Eur J Nucl Med Mol Imaging (2009) 36: 1807. doi:10.1007/s00259-009-1181-2
The aim of the study was to compare the diagnostic accuracy of 18F-fluorodeoxyglucose (FDG) PET/CT versus standard planar bone scintigraphy (BS) and 18F-labelled NaF (18F) PET for the detection of bone metastases (BM) in non-small cell lung cancer (NSCLC).
18F-FDG PET/CT was performed in 126 patients with NSCLC. Within 7 days BS (n = 58) or 18F PET (n = 68) was performed. 18F-FDG PET/CT, BS and 18F PET were evaluated by two experienced readers. Lesions were graded on a scale from 1 (definite BM) to 5 (degenerative lesion), and equivocal lesions were determined as indifferent (grade 3).
A total of 92 patients showed degenerative lesions (grade 4/5) on PET/CT, BS or 18F PET. In 34 patients (27%) BM lesions were diagnosed (grades 1 and 2). In 13 of 18 patients BM were concordantly diagnosed with PET/CT and 18F PET. PET/CT showed more BM compared to 18F PET (53 vs 40). In one patient one osteolytic BM was false-negative on 18F PET. However, 18F PET identified four patients with BM compared to negative findings on PET/CT. Of 16 patients, 11 had concordant findings of BM on PET/CT and BS. In three patients BS was false-negative and in two patients BM were diagnosed as indifferent.
Integrated 18F-FDG PET/CT is superior to BS in the detection of osteolytic BM in NSCLC. Thus, PET/CT may obviate the need to perform additional BS or 18F PET in the staging of NSCLC, which significantly reduces costs.